These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 24678935)

  • 41. Biomarkers of neurodegenerative disorders: how good are they?
    Rachakonda V; Pan TH; LE WD
    Cell Res; 2004 Oct; 14(5):347-58. PubMed ID: 15538967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proteomics Approach to Identify Biomarkers in Neurodegenerative Diseases.
    Nayak A; Salt G; Verma SK; Kishore U
    Int Rev Neurobiol; 2015; 121():59-86. PubMed ID: 26315762
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases.
    Sheta EA; Appel SH; Goldknopf IL
    Expert Rev Proteomics; 2006 Feb; 3(1):45-62. PubMed ID: 16445350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current Status of microRNA-Based Therapeutic Approaches in Neurodegenerative Disorders.
    Paul S; Bravo Vázquez LA; Pérez Uribe S; Roxana Reyes-Pérez P; Sharma A
    Cells; 2020 Jul; 9(7):. PubMed ID: 32679881
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genome-wide serum microRNA expression profiling identifies serum biomarkers for Alzheimer's disease.
    Tan L; Yu JT; Tan MS; Liu QY; Wang HF; Zhang W; Jiang T; Tan L
    J Alzheimers Dis; 2014; 40(4):1017-27. PubMed ID: 24577456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MicroRNAs in Parkinson's disease.
    Singh A; Sen D
    Exp Brain Res; 2017 Aug; 235(8):2359-2374. PubMed ID: 28526930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Circulating miRNAs as biomarkers for neurodegenerative disorders.
    Grasso M; Piscopo P; Confaloni A; Denti MA
    Molecules; 2014 May; 19(5):6891-910. PubMed ID: 24858274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuronal dark matter: the emerging role of microRNAs in neurodegeneration.
    Goodall EF; Heath PR; Bandmann O; Kirby J; Shaw PJ
    Front Cell Neurosci; 2013 Oct; 7():178. PubMed ID: 24133413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.
    Noelker C; Hampel H; Dodel R
    Mol Diagn Ther; 2011 Apr; 15(2):83-102. PubMed ID: 21623645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Competing Endogenous RNA Networks as Biomarkers in Neurodegenerative Diseases.
    Moreno-García L; López-Royo T; Calvo AC; Toivonen JM; de la Torre M; Moreno-Martínez L; Molina N; Aparicio P; Zaragoza P; Manzano R; Osta R
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33339180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of microRNAs in neurodegenerative diseases: a review.
    Li S; Lei Z; Sun T
    Cell Biol Toxicol; 2023 Feb; 39(1):53-83. PubMed ID: 36125599
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent Advances in the Roles of MicroRNA and MicroRNA-Based Diagnosis in Neurodegenerative Diseases.
    Zhang J; Chen Z; Chen H; Deng Y; Li S; Jin L
    Biosensors (Basel); 2022 Nov; 12(12):. PubMed ID: 36551041
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
    Teixeira Dos Santos MC; Bell R; da Costa AN
    Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Regulatory Network of Exosomes and microRNAs on Neurodegenerative Diseases.
    Li D; Li YP; Li YX; Zhu XH; Du XG; Zhou M; Li WB; Deng HY
    Chin Med J (Engl); 2018 Sep; 131(18):2216-2225. PubMed ID: 30203797
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of novel genomic blood biomarkers for neurodegenerative diseases.
    Borovecki F; Habek M
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):669-78. PubMed ID: 20942794
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
    Fawaz CN; Makki IS; Kazan JM; Gebara NY; Andary FS; Itani MM; El-Sayyed M; Zeidan A; Quartarone A; Darwish H; Mondello S
    Expert Rev Proteomics; 2015; 12(6):637-50. PubMed ID: 26479122
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential microRNA expression in blood in multiple sclerosis.
    Søndergaard HB; Hesse D; Krakauer M; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1849-57. PubMed ID: 23773985
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum microRNA expression profiling in patients with multiple system atrophy.
    Kume K; Iwama H; Deguchi K; Ikeda K; Takata T; Kokudo Y; Kamada M; Fujikawa K; Hirose K; Masugata H; Touge T; Masaki T
    Mol Med Rep; 2018 Jan; 17(1):852-860. PubMed ID: 29115515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles.
    Cao XY; Lu JM; Zhao ZQ; Li MC; Lu T; An XS; Xue LJ
    Neurosci Lett; 2017 Mar; 644():94-99. PubMed ID: 28223160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MicroRNA Biomarkers of Toxicity in Biological Matrices.
    Harrill AH; McCullough SD; Wood CE; Kahle JJ; Chorley BN
    Toxicol Sci; 2016 Aug; 152(2):264-72. PubMed ID: 27462126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.